Partial reversibility of cisplatin nephrotoxicity in children
- PMID: 2007926
- DOI: 10.1016/s0022-3476(05)83372-4
Partial reversibility of cisplatin nephrotoxicity in children
Abstract
To evaluate the long-term renal toxicity of cisplatin, 40 children who had been without treatment at least 18 months (range 18 months to 7 years) were observed. In all the children, glomerular filtration rate (GFR) was estimated from the plasma clearance of chromium 51-labeled ethylenediaminetetraacetic acid, both at the end of treatment and at a median follow-up of 2 years 6 months after treatment was stopped (range 18 months to 7 years). In 21 children, serum magnesium level was also measured at follow-up. Median age at diagnosis was 15 months (range 13 days to 13 years 8 months), and median cumulative doses of cisplatin was 500 mg/m2 (range 120 to 1860 mg/m2). In 22 of 24 children with an end-of-treatment GFR of less than 80 ml/min per 1.73 m2, the median improvement in GFR at follow-up was 22 ml/min per 1.73 m2 (range 2 to 56 ml/min per 1.73 m2). Hypomagnesemia was found in 6 of 21 children and was independent of GFR. No significant correlation was found between improvement in renal function and total cisplatin dose, age, gender, tumor type, or associated nephrotoxic medication. We conclude that most children have some recovery from cisplatin glomerular toxicity, especially if damage is not severe, but that hypomagnesemia may persist.
Similar articles
-
Cisplatin dose rate as a risk factor for nephrotoxicity in children.Br J Cancer. 1998 May;77(10):1677-82. doi: 10.1038/bjc.1998.276. Br J Cancer. 1998. PMID: 9635848 Free PMC article.
-
Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.Eur J Cancer. 2009 Dec;45(18):3213-9. doi: 10.1016/j.ejca.2009.06.032. Epub 2009 Oct 21. Eur J Cancer. 2009. PMID: 19850470
-
Renal toxicity of cancer chemotherapeutic agents in children: ifosfamide and cisplatin.Curr Opin Pediatr. 1995 Apr;7(2):208-13. doi: 10.1097/00008480-199504000-00016. Curr Opin Pediatr. 1995. PMID: 7787938 Review.
-
The long-term effect of cisplatin on renal function.Cancer. 1986 Nov 15;58(10):2214-7. doi: 10.1002/1097-0142(19861115)58:10<2214::aid-cncr2820581009>3.0.co;2-i. Cancer. 1986. PMID: 3756770
-
Cisplatin nephrotoxicity: experimental and clinical studies.Dan Med Bull. 1990 Feb;37(1):1-12. Dan Med Bull. 1990. PMID: 2178884 Review.
Cited by
-
Zerumbone induced apoptosis in liver cancer cells via modulation of Bax/Bcl-2 ratio.Cancer Cell Int. 2007 Apr 3;7:4. doi: 10.1186/1475-2867-7-4. Cancer Cell Int. 2007. PMID: 17407577 Free PMC article.
-
Cisplatin therapy in infants: short and long-term morbidity.Br J Cancer Suppl. 1992 Aug;18:S36-40. Br J Cancer Suppl. 1992. PMID: 1323992 Free PMC article.
-
Proceedings of the American Society of Pediatric Nephrology 1993 Education Symposium, Washington, D.C., 4 May, 1993.Pediatr Nephrol. 1994 Oct;8(5):632-40. Pediatr Nephrol. 1994. PMID: 7819017 No abstract available.
-
Identifying cisplatin-induced kidney damage in paediatric oncology patients.Pediatr Nephrol. 2018 Sep;33(9):1467-1474. doi: 10.1007/s00467-017-3765-6. Epub 2017 Aug 18. Pediatr Nephrol. 2018. PMID: 28821959 Free PMC article. Review.
-
Cisplatin dose rate as a risk factor for nephrotoxicity in children.Br J Cancer. 1998 May;77(10):1677-82. doi: 10.1038/bjc.1998.276. Br J Cancer. 1998. PMID: 9635848 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources